β-Ray brachytherapy with 106Ru plaques for retinoblastoma

Schueler, Andreas; Flühs, Dirk; Anastassiou, Gerassimos; Jurklies, Christine; Neuhäuser, Markus; Schilling, Hannah; Bornfeld, Norbert; Sauerwein, W.

doi:10.1016/j.ijrobp.2006.02.002

Cited by 57 publications

(51 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] Factors that are relevant to the clinical outcome include the tumor dose coverage and the dose to the organs at risk, such as the optic nerve, the iris, and the fovea. Because this beta radiation produces steep dose gradients, an accurate knowledge of the generated dose distributions is essential for treatment planning and clinical dose assessment.…”

Section: Introductionmentioning

confidence: 99%

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Hermida-López

2013

Medical Physics

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Hermida-López

2013

Medical Physics

View full text Add to dashboard Cite

show abstract

“…As treatment trends shifted, plaques were also used to secondarily treat or to salvage eyes that had failed systemic chemotherapy. Many reports give survival rates for previously treated eyes, and in those in which eyes predominantly received previous chemotherapy, the ocular survival percentages or rates are remarkably similar to those failing EBRT, ranging from 52% to 95% (29-31, 34, 35); this latter figure is from an article that excluded eyes with seeds (29). It appeared that the nature of the previous treatment, whether EBRT or intravenous chemotherapy, had little influence on the success of the brachytherapy-treated eyes.…”

Section: Discussionmentioning

confidence: 99%

Salvage/Adjuvant Brachytherapy After Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma

Francis

Barker

Wolden

et al. 2013

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Summary The efficacy and toxicity of brachytherapy following ophthalmic artery chemo-surgery for retinoblastoma was investigated in 15 eyes of 15 patients. This combination was effective, even in eyes with vitreous seeding, and the toxicity appeared to be no worse than reported with other radiation/chemotherapy treatments for retinoblastoma. Brachytherapy represents a potentially valuable salvage treatment for patients with recurrent retinoblastoma following ophthalmic artery chemosurgery treatment. Purpose To evaluate the efficacy and toxicity of brachytherapy after ophthalmic artery chemo-surgery (OAC) for retinoblastoma. Methods and Materials This was a single-arm, retrospective study of 15 eyes in 15 patients treated with OAC followed by brachytherapy at (blinded institution) between May 1, 2006, and December 31, 2012, with a median 19 months' follow-up from plaque insertion. Outcome measurements included patient and ocular survival, visual function, and retinal toxicity measured by electroretinogram (ERG). Results Brachytherapy was used as adjuvant treatment in 2 eyes and as salvage therapy in 13 eyes of which 12 had localized vitreous seeding. No patients developed metastasis or died of retinoblastoma. The Kaplan-Meier estimate of ocular survival was 79.4% (95% confidence interval 48.7%-92.8%) at 18 months. Three eyes were enucleated, and an additional 6 eyes developed out-of-target volume recurrences, which were controlled with additional treatments. Patients with an ocular complication had a mean interval between last OAC and plaque of 2.5 months (SD 2.3 months), which was statistically less (P= .045) than patients without ocular complication who had a mean interval between last OAC and plaque of 6.5 months (SD 4.4 months). ERG responses from pre- versus postplaque were unchanged or improved in more than half the eyes. Conclusions Brachytherapy following OAC is effective, even in the presence of vitreous seeding; the majority of eyes maintained stable or improved retinal function following treatment, as assessed by ERG.

show abstract

“…18 The dose used with Ru-106 plaques in Essen is 80 Gy to the apex, although most tumours responded with a dose of at least 50 Gy. 19 There is no comparative dosimetry of I-125 and Ru-106 and there appears to be a disparity in the doses used. They cannot simply be transposed from one isotope to the other.…”

Section: Intraocular Tumoursmentioning

confidence: 99%

Radiotherapy for ocular tumours

Stannard

Sauerwein

Maree

et al. 2012

Eye

103

View full text Add to dashboard Cite

Ocular tumours present a therapeutic challenge because of the sensitive tissues involved and the necessity to destroy the tumour while minimising visual loss. Radiotherapy (RT) is one of several modalites used apart from surgery, laser, cryotherapy, and chemotherapy. Both external beam RT (EBRT) and brachytherapy are used. Tumours of the bulbar conjunctiva, squamous carcinoma and malignant melanoma, can be treated with a radioactive plaque: strontium-90, ruthenium-106

show abstract

β-Ray brachytherapy with 106Ru plaques for retinoblastoma

Cited by 57 publications

References 21 publications

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Salvage/Adjuvant Brachytherapy After Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma

Radiotherapy for ocular tumours

Contact Info

Product

Resources

About

β-Ray brachytherapy with 106Ru plaques for retinoblastoma

Cited by 57 publications

References 21 publications

Calculation of dose distributions for 12 106Ru/106Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Calculation of dose distributions for 12 106Ru/106Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Salvage/Adjuvant Brachytherapy After Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma

Radiotherapy for ocular tumours

Contact Info

Product

Resources

About

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code

Calculation of dose distributions for 12 ¹⁰⁶Ru/¹⁰⁶Rh ophthalmic applicator models with the PENELOPE Monte Carlo code